Valneva Posts Positive Lyme Vaccine Booster Results, Pfizer Targets 2026 Regulatory Filings

Valneva SE reported positive Phase 2 study results for its Lyme disease vaccine candidate, VLA15. The study showed a strong anamnestic immune response and a favorable safety profile six months after a third booster dose. Pfizer Inc., which is developing the vaccine, aims to submit a Biologics License Application to the US FDA and Marketing Authorization Application to the European Medicines Agency in 2026.